Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Canakinumab for prevention of recurrent cardiovascular events after myocardial infarction
2010-022970-14Phase 3Terminated
- Sponsor
- Novartis
- Start
- May 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in atherosclerotic disease and myocardial infarction (MI) comparing Canakinumab with Placebo (2 arms). Started May 2011; status: terminated.
02
Drugs
canakinumab
03
Conditions
atherosclerotic diseasemyocardial infarction (MI)
Beyond the preview
Go deeper on 2010-022970-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-022970-14.